Please use this identifier to cite or link to this item:
|Title: ||YC-1 inhibits proliferation of breast cancer cells by downregulating EZH2 expression via activation of c-Cbl and ERK|
|Authors: ||Chang, LC;Chang, LC;Lin, HY;Lin, HY;Tsai, MT;Tsai, MT;鄒瑞煌;Chou, Ruey-Hwang;Lee, FY;Lee, FY;Teng, CM;Teng, CM;Hsieh, MT;Hsieh, MT;Hung, HY;Hung, HY;Huang LJ,;余永倫;Kuo, SC;Kuo, SC|
|Issue Date: ||2014-06-04 10:23:09 (UTC+8)|
|Abstract: ||YC-1 exhibits potent anticancer activity via numerous actions in many cancer cell lines. Hence, we investigated the in vivo antitumour efficacy of YC-1 in an MDA-MB-468 xenograft model and elucidated the mechanism of down-regulation of enhancer of zeste homology 2 (EZH2) by YC-1 in breast cancer cells.
In YC-1-treated breast cancer cells and tumour specimens from YC-1-treated MDA-MB-468 xenografts, EZH2 expression was analysed by Western blotting. Pharmacological inhibitors and short hairpin RNA-mediated knockdown were applied to identify possible signalling pathways involved in EZH2 down-regulation by YC-1.
YC-1 reduced the viability of breast cancer cells and tumour growth in MDA-MB-468 xenografts. In breast cancer cells, YC-1 down-regulated EZH2 expression in a concentration- and time-dependent manner. Depletion of EZH2 reduced the proliferation and susceptibility of breast cancer cells to YC-1-induced apoptosis. EZH2 expression was suppressed in tumour specimens from YC-1-treated MDA-MB-468 xenograft mice. YC-1 enhanced both the degradation rate and ubiquitination of EZH2. The down-regulation of EZH2 by YC-1 was associated with activation of PKA and Src-Raf-ERK-mediated signalling pathways. Furthermore, depletion of Casitas B-lineage lymphoma (c-Cbl), an E3 ubiquitin ligase, abolished YC-1-induced apoptosis and suppression of EZH2. YC-1 rapidly activated c-Cbl to induce signalling associated with ERK and EZH2.
CONCLUSION AND IMPLICATIONS:
We discovered that YC-1 induces apoptosis and inhibits tumour growth of breast cancer cells via down-regulation of EZH2 by activating c-Cbl and ERK. These data suggest that YC-1 is a potential anticancer drug candidate for triple-negative breast cancer.
|Relation: ||BRITISH JOURNAL OF PHARMACOLOGY, 171(17):4010-25.|
|Appears in Collections:||[生物科技學系] 期刊論文|
Files in This Item:
All items in ASIAIR are protected by copyright, with all rights reserved.